Navigation Links
Robbins & Myers Reports Record Third Quarter Results
Date:6/30/2008

e third quarter, a 22% increase, and orders of $84 million, an 8% increase. Excluding the effects of currency exchange rates and an acquisition, sales increased 12% and orders decreased 1% following 22% year-over-year organic order growth in the second quarter. The segment earned $10 million of EBIT in the third quarter, and EBIT margins improved 470 basis points to 12.6%.

The Romaco segment reported sales growth of 20% with sales of $37 million in the third quarter, and orders were up 3% to $34 million. Excluding the impact from currency exchange rates, sales increased 3% and orders declined 15%, following 26% year-over-year organic order growth in the second quarter. Excluding the $6 million benefit from the March 2006 product line sales, Romaco adjusted EBIT margins improved 80 basis points to 6.0% as a result of increased sales.

Conference Call to Be Held Today at 11:00 AM (EDT)

A conference call to discuss these results has been scheduled for 11:00 a.m. EDT Monday, June 30, 2008, which can be accessed at http://www.robn.com or by dialing 888-286-8010 (US/Canada) or +1-617-801-6888, using conference ID # 63192398. Replays of the call can be accessed by dialing 888-286-8010 (U.S./Canada) or +1-617-801-6888, both using replay ID # 63192398.

About Robbins & Myers

Robbins & Myers, Inc. is a leading supplier of engineered equipment and systems for critical applications in global energy, industrial, chemical and pharmaceutical markets.

In this release the Company refers to various non-GAAP measures, including EBIT, Adjusted EBIT, EBITDA (earnings before interest, taxes, depreciation and amortization) and Adjusted EBITDA. The Company uses these measures to evaluate its performance and believes these measures are helpful to investors in assessing its performance. Reconciliations of these measures to comparable GAAP measures are provided further below in this release.

In addi
'/>"/>

SOURCE Robbins & Myers, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Robbins & Myers Schedules Third Quarter Fiscal 2008 Financial Results Conference Call
2. Robbins & Myers Reports Additional Gain and Increases Earnings Guidance
3. Robbins & Myers Schedules Second Quarter Fiscal 2008 Financial Results Conference Call
4. Robbins & Myers to Present at Gabelli Conference
5. Robbins & Myers to Present at Merrill Lynch Growth Industrials Conference December 13, 2007
6. Robbins & Myers Presenting at Bear Stearns 3rd Annual Commodities and Capital Goods Conference November 28, 2007
7. Robbins Bros. Gives Water at AIDS Walk L.A.
8. Robbins & Myers Announces Regular Quarterly Cash Dividend
9. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
10. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
11. Former Bristol-Myers Squibb Senior Vice President Indicted for Lying to the Federal Government About Popular Blood-Thinning Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... A short, preoperative team briefing prior to cardiac ... - improves communication and reduces errors and costs, according ... Mayo researchers believe this is the first such study ... preoperative briefings on specific disruptions to surgery. Disruptions were ...
... fires, elected officials and city managers gather to prepare ... The Los Angeles County Department of Public Health today ... at your Doorstep," designed to educate elected officials and ... More than one hundred participants attended the workshop from ...
... of the recently updated 2009 editions of two ... products industry. According to Market Scope, this is ... market. New anti-VEGF therapies are successfully treating vision-threatening ... been largely untreatable. Investigational devices are promising to ...
... Systems, Inc. today announced that the Frisco Independent ... Model 615 on four occasions during the first ... President of Operations.(Logo: http://www.newscom.com/cgi-bin/prnh/20051215/OXYSURELOGO ... in its first month of implementation, only solidifies ...
... Affordable Wristbands Access to Emergency Info LAHAINA, Hawaii, ... new product originally intended for athletes, yet appealing ... simple personal safety solution. The XtremeSportsID band is ... medical alert symbol, a unique 8-digit code, and ...
... software now availableINDIANAPOLIS, May 26 ProSolv CardioVascular, ... the commercial availability of Synapse(TM) ProSolv(R) ... integration with QLAB advanced quantification software from Philips ... been designed to enhance clinical workflow, help improve ...
Cached Medicine News:Health News:Mayo Study Finds That Team Preop Briefing Improves Communication, Reduces Errors 2Health News:Mayo Study Finds That Team Preop Briefing Improves Communication, Reduces Errors 3Health News:Mayo Study Finds That Team Preop Briefing Improves Communication, Reduces Errors 4Health News:County and City Leaders Coordinate to Just Be Ready 2Health News:Market Scope Expects Retina Pharmaceutical Industry to Top $3.5 Billion by 2014 2Health News:Market Scope Expects Retina Pharmaceutical Industry to Top $3.5 Billion by 2014 3Health News:Market Scope Expects Retina Pharmaceutical Industry to Top $3.5 Billion by 2014 4Health News:Frisco ISD Treats Four Students in Medical Emergencies With OxySure(R) Model 615 2Health News:Frisco ISD Treats Four Students in Medical Emergencies With OxySure(R) Model 615 3Health News:Frisco ISD Treats Four Students in Medical Emergencies With OxySure(R) Model 615 4Health News:New Wristband May Save Lives 2Health News:New Wristband May Save Lives 3Health News:ProSolv Version 4.0.2 Makes Commercial Debut at ASE 2
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... 40/12.5 and 40/25 mg/day and Amlodipine +,Benazepril ... Society of,Hypertension Twenty-Second Annual Scientific Meeting, PARSIPPANY, ... data,presented today at the American Society of ... Chicago,demonstrated that the fixed-dose combination Benicar HCT,(olmesartan ...
... Calif.--(BUSINESS WIRE)--May,21, 2007 - ChemGenex Pharmaceuticals (ASX: ... clinical data relevant to the development,strategy for ... T315I mutation in Philadelphia-positive leukemias",by researchers Simona ... Italy (Haematologica Volume 92, pages 401-404) offers,insight ...
Cached Medicine Technology:Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 2Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 3Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 4Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 5Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 6Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 7Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 8Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 2Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 3
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
This unit is the finest standalone handswitch bipolar unit available....
...
...
Medicine Products: